Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction
Clinical and Investigative Medicine · 31.05.2015 · 38 (3) · E100-E109
DOI: 10.25011/cim.v38i3.22705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Investigative Medicine, erschienen am 31.05.2015. Verfasst von Wei-Chin Hung und 9 weiteren Autor:innen. Beteiligte Einrichtung: . email@email.com. Die Arbeit wurde bisher 23-mal zitiert (Crossref).
Abstract (Originalsprache)
Purpose
Circulating levels of visfatin, a ubiquitous adipokine, may reflect both the severity of plaque as well as degree of plaque stabilization in acute myocardial injury. The purpose of this study was to test whether the level of visfatin is associated with the occurrence of major adverse cardiovascular events (MACEs) in patients with acute ST-elevation myocardial infarction (STEMI).
Methods
Consecutive patients (n=185) with acute STEMI were prospectively enrolled in the study. ELISA was used to measure plasma visfatin concentrations. Composite MACEs included death, recurrent myocardial infarction, target lesion revascularization or re-advanced heart failure.
Results
Plasma visfatin levels were significantly higher in composite MACE patients than in non-MACE patients. A multivariate Cox hazard regression model revealed that the predictive independent risk factors for the occurrence of composite MACEs were visfatin level (relative risk = 1.04) and age (relative risk = 6.05). When patients were grouped according to their plasma visfatin levels, composite MACEs occurred more frequently in patients presenting with high visfatin levels. Moreover, Kaplan-Meier analysis revealed that high visfatin levels were significantly associated with the occurrence of composite MACEs.
Conclusions
The level of plasma visfatin may be associated with risk of composite MACEs in STEMI patients, and may be useful for risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- . email@email.com.
Zitieren
APA
Hung, W. C., Yu, T. H., Hsu, C. C., Lu, L. F., Chung, F. M., Tsai, I. T., Lu, Y. C., Houng, J. Y., Lee, Y. J., & Wang, C. P. (2015). Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction. Clinical and Investigative Medicine, 38(3), E100-E109. https://doi.org/10.25011/cim.v38i3.22705
Vancouver
Hung WC, Yu TH, Hsu CC, Lu LF, Chung FM, Tsai IT, et al. Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction. Clinical and Investigative Medicine. 2015;38(3):E100-E109. doi:10.25011/cim.v38i3.22705
BibTeX
@article{Hung2015,
author = {Hung, Wei-Chin and Yu, Teng-Hung and Hsu, Chia-Chang and Lu, Li-Fen and Chung, Fu-Mei and Tsai, I-Ting and Lu, Yung-Chuan and Houng, Jer-Yiing and Lee, Yau-Jiunn and Wang, Chao-Ping},
title = {Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction},
journal = {Clinical and Investigative Medicine},
year = {2015},
volume = {38},
number = {3},
pages = {E100--E109},
doi = {10.25011/cim.v38i3.22705}
}
EUVIMED